TrkB Protein
Overview
TrkB (tropomyosin receptor kinase B), also known as tyrosine receptor kinase B or NTRK2 (neurotrophic tyrosine kinase receptor type 2), is a transmembrane receptor tyrosine kinase encoded by the NTRK2 gene located on chromosome 9q22.1 in humans. TrkB is a principal receptor for brain-derived neurotrophic factor (BDNF), one of the most abundant neurotrophic factors in the central and peripheral nervous systems. This receptor plays critical roles in neuronal survival, differentiation, synaptic plasticity, and long-term potentiation—processes fundamental to learning, memory, and nervous system maintenance. Dysregulation of TrkB signaling has emerged as a significant factor in multiple neurodegenerative diseases, making it an important target for both basic research and therapeutic development.
Function/Biology
TrkB belongs to the family of neurotrophic tyrosine kinase receptors and exists in multiple functional forms generated through alternative splicing. The full-length isoform (TrkB-FL) contains a complete tyrosine kinase domain, while truncated isoforms (TrkB-T1 and TrkB-T2) lack kinase domains and function as dominant-negative regulators. Upon BDNF binding, TrkB undergoes homodimerization and autophosphorylation of critical tyrosine residues (Y516 and Y515) in its activation loop, enabling recruitment and activation of downstream signaling molecules.
...TrkB Protein
Overview
TrkB (tropomyosin receptor kinase B), also known as tyrosine receptor kinase B or NTRK2 (neurotrophic tyrosine kinase receptor type 2), is a transmembrane receptor tyrosine kinase encoded by the NTRK2 gene located on chromosome 9q22.1 in humans. TrkB is a principal receptor for brain-derived neurotrophic factor (BDNF), one of the most abundant neurotrophic factors in the central and peripheral nervous systems. This receptor plays critical roles in neuronal survival, differentiation, synaptic plasticity, and long-term potentiation—processes fundamental to learning, memory, and nervous system maintenance. Dysregulation of TrkB signaling has emerged as a significant factor in multiple neurodegenerative diseases, making it an important target for both basic research and therapeutic development.
Function/Biology
TrkB belongs to the family of neurotrophic tyrosine kinase receptors and exists in multiple functional forms generated through alternative splicing. The full-length isoform (TrkB-FL) contains a complete tyrosine kinase domain, while truncated isoforms (TrkB-T1 and TrkB-T2) lack kinase domains and function as dominant-negative regulators. Upon BDNF binding, TrkB undergoes homodimerization and autophosphorylation of critical tyrosine residues (Y516 and Y515) in its activation loop, enabling recruitment and activation of downstream signaling molecules.
The primary signaling pathways initiated by activated TrkB include the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) pathway, which promotes neuronal survival and metabolism, and the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway, which regulates gene expression and synaptic function. Additionally, TrkB activation recruits phospholipase Cγ (PLCγ), generating second messengers that modulate intracellular calcium levels and activate protein kinase C (PKC). These coordinated signaling cascades support neuronal growth cone extension, axonal elongation, dendritic spine maturation, and synaptic transmission strength.
Beyond BDNF, TrkB is also activated by brain-derived neurotrophic factor's precursor form (proBDNF) and other neurotrophins, though with lower affinity. TrkB is expressed throughout the nervous system, with particularly high levels in the hippocampus, prefrontal cortex, and striatum—regions critical for learning, memory, and motor control.
Role in Neurodegeneration
TrkB signaling dysfunction represents a common pathological feature across multiple neurodegenerative diseases. In Alzheimer's disease, reduced BDNF-TrkB signaling correlates with cognitive decline, synaptic loss, and amyloid-β accumulation. Amyloid-β oligomers directly impair BDNF-TrkB signaling and promote neuroinflammation, creating a vicious cycle of receptor dysfunction and neuronal death.
In Parkinson's disease, diminished TrkB signaling in the substantia nigra contributes to dopaminergic neuron vulnerability and loss. Progressive TrkB downregulation precedes motor symptom onset, suggesting its role in disease initiation. In Huntington's disease, mutant huntingtin protein impairs BDNF production and TrkB-dependent survival signaling in striatal neurons, exacerbating selective vulnerability of medium spiny neurons.
ALS pathology involves compromised TrkB function in motor neurons and their target muscles, reducing neuromuscular junction stability and motor neuron survival. Reduced BDNF-TrkB signaling accelerates disease progression in both familial and sporadic ALS cases.
Molecular Mechanisms
TrkB dysfunction in neurodegeneration operates through multiple mechanisms. Reduced BDNF availability—due to decreased production, impaired trafficking, or proteolytic cleavage—limits TrkB activation. Pathological proteins characteristic of each neurodegeneration disease (amyloid-β, tau, α-synuclein, mutant huntingtin, misfolded SOD1) directly interfere with TrkB internalization, receptor trafficking, or downstream signaling cascade activation.
Aberrant kinase activity represents another dysfunction mode, including reduced autophosphorylation capacity or impaired recruitment of signaling adaptors. Oxidative stress and neuroinflammation degrade TrkB expression and promote its degradation through proteasomal pathways. Additionally, dysregulated truncated TrkB isoforms that lack kinase activity can competitively inhibit full-length receptor signaling.
Clinical/Research Significance
TrkB represents a promising therapeutic target for neurodegenerative diseases. Small-molecule TrkB agonists and BDNF mimetics are in development to enhance receptor activation independent of BDNF availability. Strategies to increase BDNF production through physical exercise, enriched environments, or direct gene therapy show neuroprotective potential in preclinical models. TrkB modulation combined with disease-modifying therapies targeting pathological protein aggregation may provide synerg